Jazz Pharmaceuticals (JAZZ) to Release Earnings on Tuesday

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Jazz Pharmaceuticals to post earnings of ($5.61) per share and revenue of $1.05 billion for the quarter. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.000-5.600 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The business had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter last year, the business posted $2.68 EPS. The business's revenue was down .5% compared to the same quarter last year. On average, analysts expect Jazz Pharmaceuticals to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Trading Up 0.2%

JAZZ stock traded up $0.22 during midday trading on Friday, hitting $118.23. The company had a trading volume of 549,702 shares, compared to its average volume of 632,451. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $148.06. The stock's 50 day moving average price is $110.22 and its 200 day moving average price is $118.07. The stock has a market cap of $7.15 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 5.68 and a beta of 0.32.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Morgan Stanley reduced their target price on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada cut their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $181.64.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer directly owned 439,307 shares of the company's stock, valued at $51,113,369.45. The trade was a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan bought 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director directly owned 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 2,500 shares of company stock valued at $277,930. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. Geneos Wealth Management Inc. increased its position in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 137 shares during the period. Acadian Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $90,000. Focus Partners Wealth increased its position in Jazz Pharmaceuticals by 3.4% during the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock worth $574,000 after purchasing an additional 154 shares during the period. Royal Bank of Canada increased its position in Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock worth $8,394,000 after purchasing an additional 33,210 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock worth $24,479,000 after acquiring an additional 7,954 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.